Clemastine fumarate promotes myelin repair of chronic lesions of the non-human primate optic nerve
Nadege Sarrazin, Rafik Arab, Elena Brazhnikova, Christian Cordano, Jeremy Chazot, Fabrice Arcizet, Corinne Bachelin, Pierre Moissonnier, Céline Nouvel-Jaillard, Ari Green, Pierre Pouget, Anne Baron-Van Evercooren · FENS Forum 2024
In the recent years, several pro-myelinating agents have been identified (Melchor et al., 2019). Among them, clemastine fumarate an anti-muscarinic compound, has been recognized as a potent agent promoting anatomical and clinical recovery in rodents (Mei et al., 2014, Cordano et al., 2023) and primary efficacy in clinic (Green et al., 2017). Although the clinical trial REBUILD showed reduced visual evoked latencies (VEP) in RRMS patients treated with clemastine, the impact of clemastine on myelin repair in the absence of post-mortem validation, remained elusive. We took advantage of a recently
ePoster · Neuroscience